199730 — BioInfra Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual income statement for BioInfra Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	30,555	35,427	30,129	23,833	23,148
Cost of Revenue
Gross Profit	12,031	13,972	9,553	5,696	5,325
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	23,093	29,070	28,826	28,953	29,428
Operating Profit	7,463	6,358	1,302	-5,120	-6,280
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	7,099	6,987	1,279	-5,876	-8,125
Provision for Income Taxes
Net Income After Taxes	6,234	6,237	2,002	-3,976	-9,131
Net Income Before Extraordinary Items
Net Income	6,234	6,237	2,002	-3,976	-9,131
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	6,234	6,237	2,002	-3,976	-9,131
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,294	1,316	426	-820	-1,875
Dividends per Share